Evidence map›Paper›PMID 38542517›Full record

ArticleInternational journal of molecular sciences2024

Metabolomics of Plasma in XLH Patients with Arterial Hypertension: New Insights into the Underlying Mechanisms.

Luis Carlos López-Romero, José Jesús Broseta, Marta Roca-Marugán, Juan R Muñoz-Castañeda, Agustín Lahoz, Julio Hernández-Jaras

Abstract readMulticenter Study
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Luis Carlos López-RomeroDepartment of Nephrology, Consorci Hospital General Universitari de València, 46014 Valencia, Spain.ORCID 0000-0002-5986-8811
José Jesús BrosetaDepartment of Nephrology and Renal Transplantation, Hospital Clínic of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0002-4559-9083
Marta Roca-MarugánMetabolomics Unit, Health Research Institute Hospital La Fe (IIS La Fe), 46026 Valencia, Spain.ORCID 0000-0003-0708-6364
Juan R Muñoz-CastañedaMaimonides Institute for Biomedical Research of Córdoba (IMIBIC), Nephrology Clinical Management Unit, Reina Sofia Hospital/University of Cordoba, 14071 Córdoba, Spain.ORCID 0000-0002-9341-0724
Agustín LahozBiomarkers and Precision Medicine Unit, Health Research Institute-Hospital La Fe, 46026 Valencia, Spain.ORCID 0000-0001-7232-0626
Julio Hernández-JarasDepartment of Nephrology, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain.ORCID 0000-0003-1250-1550

Funding

Kyowa Kirin International (United Kingdom) NA
6 · The paper itself

Abstract

X-linked hypophosphatemia (XLH) is a rare genetic disorder that increases fibroblast growth factor 23 (FGF23). XLH patients have an elevated risk of early-onset hypertension. The precise factors contributing to hypertension in XLH patients have yet to be identified. A multicenter cross-sectional study of adult patients diagnosed with XLH. Metabolomic analysis was performed using ultra-performance liquid chromatography (UPLC) coupled to a high-resolution mass spectrometer. Twenty subjects were included, of which nine (45%) had hypertension. The median age was 44 years. Out of the total, seven (35%) subjects had a family history of hypertension. No statistically significant differences were found between both groups for nephrocalcinosis or hyperparathyroidism. Those with hypertension exhibited significantly higher levels of creatinine (1.08 ± 0.31 mg/dL vs. 0.78 ± 0.19 mg/dL;

Indexed as

Familial Hypophosphatemic RicketsHypertensionAdultCross-Sectional StudiesFibroblast Growth FactorsHumansFibroblast Growth Factorscardiovascular riskFGF23fibroblast growth factor 23hypertensionhypophosphatemiatubulopathyXLHX-linked hypophosphatemia

Identifiers

PMID38542517
PMCPMC10971556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.